Targeting cancer with small molecule kinase inhibitors (original) (raw)

• Cohen, P. Protein kinases — the major drug targets of the twenty-first century? Nature Rev. Drug Discov. 1, 309–315 (2002).
  CAS Google Scholar
• Daley, G. Q., Van Etten, R. A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824–830 (1990).
  CAS PubMed Google Scholar
• Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408–2417 (2006).
  CAS PubMed Google Scholar
• Davies, S. P., Reddy, H., Caivano, M. & Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95–105 (2000).
  CAS PubMed PubMed Central Google Scholar
• Lombardo, L. J. et al. Discovery of _N_-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658–6661 (2004). This paper documents the discovery of dasatinib using a medicinal chemistry approach.
  CAS PubMed Google Scholar
• Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399–401 (2004). This study showed that dasatinib inhibits many imatinib-resistant BCR–ABL1 mutants.
  CAS PubMed Google Scholar
• O'Brien, S. G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994–1004 (2003).
  CAS PubMed Google Scholar
• Weinstein, I. B. et al. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin. Cancer Res. 3, 2696–2702 (1997).
  CAS PubMed Google Scholar
• Weinstein, I. B. & Joe, A. K. Mechanisms of disease: Oncogene addiction — a rationale for molecular targeting in cancer therapy. Nature Clin. Pract. Oncol. 3, 448–457 (2006).
  CAS Google Scholar
• Futreal, P. A. et al. A census of human cancer genes. Nature Rev. Cancer 4, 177–183 (2004). This article features an impressive compilation of genes known to be mutated in cancer.
  CAS Google Scholar
• Forbes, S. et al. Cosmic 2005. Br. J. Cancer 94, 318–322 (2006).
  CAS PubMed PubMed Central Google Scholar
• Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
  CAS PubMed Google Scholar
• Bachman, K. E. et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 3, 772–775 (2004).
  CAS PubMed Google Scholar
• Samuels, Y. et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561–573 (2005).
  CAS PubMed Google Scholar
• Garnett, M. J. & Marais, R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6, 313–319 (2004).
  CAS PubMed Google Scholar
• Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
  CAS PubMed Google Scholar
• Morgan, K. J. & Gilliland, D. G. A role for JAK2 mutations in myeloproliferative diseases. Annu. Rev. Med. 59, 213–222 (2008).
  CAS PubMed Google Scholar
• Mosse, Y. P. et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930–935 (2008).
  CAS PubMed PubMed Central Google Scholar
• Kaelin, W. G. Jr. The concept of synthetic lethality in the context of anticancer therapy. Nature Rev. Cancer 5, 689–698 (2005).
  CAS Google Scholar
• Wang, J. Y., Wilcoxen, K. M., Nomoto, K. & Wu, S. Recent advances of MEK inhibitors and their clinical progress. Curr. Top. Med. Chem. 7, 1364–1378 (2007).
  CAS PubMed Google Scholar
• Faivre, S., Kroemer, G. & Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nature Rev. Drug Discov. 5, 671–688 (2006).
  CAS Google Scholar
• Hu, Y. et al. 90-kDa ribosomal S6 kinase is a direct target for the nuclear fibroblast growth factor receptor 1 (FGFR1): role in FGFR1 signaling. J. Biol. Chem. 279, 29325–29335 (2004).
  CAS PubMed Google Scholar
• Malumbres, M. & Barbacid, M. Cell cycle kinases in cancer. Curr. Opin. Genet. Dev. 17, 60–65 (2007). A comprehensive review of the cell cycle kinases currently being developed as targets for novel inhibitors.
  CAS PubMed Google Scholar
• Geiger, T. R. & Peeper, D. S. Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. Cancer Res. 67, 6221–6229 (2007).
  CAS PubMed Google Scholar
• Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med. 358, 2039–2049 (2008).
  CAS PubMed PubMed Central Google Scholar
• Christofk, H. R. et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230–233 (2008).
  CAS PubMed Google Scholar
• Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153–158 (2007).
  CAS PubMed PubMed Central Google Scholar
• Jia, S. et al. Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis. Nature 454, 776–779 (2008).
  CAS PubMed PubMed Central Google Scholar
• Wee, S. et al. PTEN-deficient cancers depend on PIK3CB. Proc. Natl Acad. Sci. USA 105, 13057–13062 (2008).
  CAS PubMed PubMed Central Google Scholar
• Johnson, L. N., Lowe, E. D., Noble, M. E. & Owen, D. J. The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases. FEBS Lett. 430, 1–11 (1998).
  CAS PubMed Google Scholar
• Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002).
  CAS PubMed Google Scholar
• Traxler, P. & Furet, P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther. 82, 195–206 (1999).
  CAS PubMed Google Scholar
• Liu, Y. & Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations. Nature Chem. Biol. 2, 358–364 (2006).
  CAS Google Scholar
• Hennequin, L. F. et al. N.-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2_H_-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J. Med. Chem. 49, 6465–6488 (2006).
  CAS PubMed Google Scholar
• Manley, P. W., Cowan-Jacob, S. W. & Mestan, J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim. Biophys. Acta 1754, 3–13 (2005).
  CAS PubMed Google Scholar
• Wan, P. T. et al. Mechanism of activation of the RAF–ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855–867 (2004).
  CAS PubMed Google Scholar
• Knight, Z. A. et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125, 733–747 (2006). An impressive illustration of the integration of chemical and biological approaches to discover and characterize isoform-selective PI3K inhibitors.
  CAS PubMed PubMed Central Google Scholar
• Ohren, J. F. et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nature Struct. Mol. Biol. 11, 1192–1197 (2004).
  CAS Google Scholar
• Adrian, F. J. et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nature Chem. Biol. 2, 95–102 (2006).
  CAS Google Scholar
• Barnett, S. F. et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 385, 399–408 (2005).
  CAS PubMed PubMed Central Google Scholar
• Lindsley, C. W. et al. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 15, 761–764 (2005).
  CAS PubMed Google Scholar
• McIntyre, K. W. et al. A highly selective inhibitor of IκB kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum. 48, 2652–2659 (2003).
  CAS PubMed Google Scholar
• Grimsby, J. et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301, 370–373 (2003).
  CAS PubMed Google Scholar
• Guertin, K. R. & Grimsby, J. Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy. Curr. Med. Chem. 13, 1839–1843 (2006).
  CAS PubMed Google Scholar
• Sullivan, J. E. et al. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett. 353, 33–36 (1994).
  CAS PubMed Google Scholar
• Sanders, M. J. et al. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J. Biol. Chem. 282, 32539–32548 (2007).
  CAS PubMed Google Scholar
• Cohen, M. S., Zhang, C., Shokat, K. M. & Taunton, J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308, 1318–1321 (2005). This study is an instructive example of how a selective irreversible inhibitor of RSK was designed.
  CAS PubMed PubMed Central Google Scholar
• Kwak, E. L. et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl Acad. Sci. USA 102, 7665–7670 (2005).
  CAS PubMed PubMed Central Google Scholar
• Rabindran, S. K. et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 64, 3958–3965 (2004).
  CAS PubMed Google Scholar
• Kobayashi, S. et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 65, 7096–7101 (2005).
  CAS PubMed Google Scholar
• Fry, D. W. et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265, 1093–1095 (1994).
  CAS PubMed Google Scholar
• Heymach, J. V., Nilsson, M., Blumenschein, G., Papadimitrakopoulou, V. & Herbst, R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin. Cancer Res. 12, 4441s–4445s (2006).
  CAS PubMed Google Scholar
• Felip, E., Santarpia, M. & Rosell, R. Emerging drugs for non-small-cell lung cancer. Expert Opin. Emerg. Drugs 12, 449–460 (2007).
  CAS PubMed Google Scholar
• Wissner, A. et al. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. Bioorg. Med. Chem. 15, 3635–3648 (2007).
  CAS PubMed Google Scholar
• Pan, Z. et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2, 58–61 (2007).
  CAS PubMed Google Scholar
• Cohen, M. S., Hadjivassiliou, H. & Taunton, J. A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. Nature Chem. Biol. 3, 156–160 (2007).
  CAS Google Scholar
• Schirmer, A., Kennedy, J., Murli, S., Reid, R. & Santi, D. V. Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. Proc. Natl Acad. Sci. USA 103, 4234–4239 (2006).
  CAS PubMed PubMed Central Google Scholar
• Li, B., Liu, Y., Uno, T. & Gray, N. Creating chemical diversity to target protein kinases. Comb. Chem. High Throughput Screen 7, 453–472 (2004).
  CAS PubMed Google Scholar
• Kraker, A. J. et al. Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-_d_]pyrimidine tyrosine kinase inhibitors. Biochem. Pharmacol. 60, 885–898 (2000).
  CAS PubMed Google Scholar
• Mohammadi, M. et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 17, 5896–5904 (1998).
  CAS PubMed PubMed Central Google Scholar
• Lenart, P. et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr. Biol. 17, 304–315 (2007).
  CAS PubMed Google Scholar
• Sapkota, G. P. et al. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem. J. 401, 29–38 (2007).
  CAS PubMed Google Scholar
• Scotlandi, K. et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 65, 3868–3876 (2005).
  CAS PubMed Google Scholar
• Okram, B. et al. A general strategy for creating “inactive-conformation” abl inhibitors. Chem. Biol. 13, 779–786 (2006).
  CAS PubMed Google Scholar
• Dubinina, G. G. et al. In silico design of protein kinase inhibitors: successes and failures. Anticancer Agents Med. Chem. 7, 171–188 (2007).
  CAS PubMed Google Scholar
• Gill, A. New lead generation strategies for protein kinase inhibitors — fragment based screening approaches. Mini Rev. Med. Chem. 4, 301–311 (2004).
  CAS PubMed Google Scholar
• Wyatt, P. G. et al. Identification of _N_-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1_H_-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J. Med. Chem. 51, 4986–4999 (2008).
  CAS PubMed Google Scholar
• Bain, J. et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297–315 (2007).
  CAS PubMed PubMed Central Google Scholar
• Venter, J. C. et al. The sequence of the human genome. Science 291, 1304–1351 (2001).
  CAS PubMed Google Scholar
• Carter, T. A. et al. Inhibition of drug-resistant mutants of, ABL, KIT, and EGF receptor kinases. Proc. Natl Acad. Sci. USA 102, 11011–11016 (2005).
  CAS PubMed PubMed Central Google Scholar
• Fabian, M. A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnol. 23, 329–336 (2005).
  CAS Google Scholar
• Harrington, E. A. et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nature Med. 10, 262–267 (2004).
  CAS PubMed Google Scholar
• Young, M. A. et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 66, 1007–1014 (2006).
  CAS PubMed Google Scholar
• Fedorov, O. et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl Acad. Sci. USA 104, 20523–20528 (2007).
  CAS PubMed PubMed Central Google Scholar
• Warmuth, M., Kim, S., Gu, X. J., Xia, G. & Adrian, F. Ba/F3 cells and their use in kinase drug discovery. Curr. Opin. Oncol. 19, 55–60 (2007).
  CAS PubMed Google Scholar
• Melnick, J. S. et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc. Natl Acad. Sci. USA 103, 3153–3158 (2006).
  CAS PubMed PubMed Central Google Scholar
• Godl, K. et al. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl Acad. Sci. USA 100, 15434–15439 (2003).
  CAS PubMed PubMed Central Google Scholar
• Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nature Biotechnol. 25, 1035–1044 (2007).
  CAS Google Scholar
• Peters, E. C. & Gray, N. S. Chemical proteomics identifies unanticipated targets of clinical kinase inhibitors. ACS Chem. Biol. 2, 661–664 (2007).
  CAS PubMed Google Scholar
• le Coutre, P. et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95, 1758–1766 (2000).
  CAS PubMed Google Scholar
• Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–1043 (2007). This article describes upregulation of an alternative pathway as a mechanism of resistance to kinase inhibitors.
  CAS PubMed Google Scholar
• Chu, S. et al. Detection of BCR–ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 105, 2093–2098 (2005).
  CAS PubMed Google Scholar
• Hughes, T. & Branford, S. Molecular monitoring of BCR–ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev. 20, 29–41 (2006).
  CAS PubMed Google Scholar
• Roumiantsev, S. et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc. Natl Acad. Sci. USA 99, 10700–10705 (2002).
  CAS PubMed PubMed Central Google Scholar
• Fletcher, J. A. & Rubin, B. P. KIT mutations in GIST. Curr. Opin. Genet. Dev. 17, 3–7 (2007).
  CAS PubMed Google Scholar
• Cools, J. et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res. 64, 6385–6389 (2004).
  CAS PubMed Google Scholar
• Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319–325 (2002).
  CAS PubMed Google Scholar
• Copland, M. et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107, 4532–4539 (2006).
  CAS PubMed Google Scholar
• Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).
  PubMed PubMed Central Google Scholar
• Blencke, S. et al. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem. Biol. 11, 691–701 (2004). This article provides an impressive illustration of the general importance of the gatekeeper position.
  CAS PubMed Google Scholar
• Gumireddy, K. et al. A non-ATP-competitive inhibitor of BCR–ABL overrides imatinib resistance. Proc. Natl Acad. Sci. USA 102, 1992–1997 (2005).
  CAS PubMed PubMed Central Google Scholar
• Gumireddy, K. et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7, 275–286 (2005).
  CAS PubMed Google Scholar
• Gorre, M. E., Ellwood-Yen, K., Chiosis, G., Rosen, N. & Sawyers, C. L. BCR–ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR–ABL chaperone heat shock protein 90. Blood 100, 3041–3044 (2002).
  CAS PubMed Google Scholar
• Copland, M. et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergises with tyrosine kinase inhibitors. Blood 111, 2843–2853 (2008).
  CAS PubMed Google Scholar
• Hamby, J. M. et al. Structure-activity relationships for a novel series of pyrido[2,3-_d_]pyrimidine tyrosine kinase inhibitors. J. Med. Chem. 40, 2296–2303 (1997).
  CAS PubMed Google Scholar
• Kothe, M. et al. Selectivity-determining residues in Plk1. Chem. Biol. Drug Des. 70, 540–546 (2007).
  CAS PubMed Google Scholar
• Weisberg, E. et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr–Abl. Cancer Cell 7, 129–141 (2005).
  CAS PubMed Google Scholar
• Shah, N. P. et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108, 286–291 (2006).
  CAS PubMed Google Scholar
• Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnol. 26, 127–132 (2008). This article features an impressive profiling of inhibitors against a large panel of kinases.
  CAS Google Scholar
• Vajpai, N. et al. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J. Biol. Chem. 283, 18292–18302 (2008).
  CAS PubMed Google Scholar
• Zhou, T. et al. Crystal structure of the T315I mutant of AbI kinase. Chem. Biol. Drug Des. 70, 171–181 (2007).
  CAS PubMed Google Scholar
• Modugno, M. et al. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res. 67, 7987–7990 (2007).
  CAS PubMed Google Scholar
• Carpinelli, P. et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol. Cancer Ther. 6, 3158–3168 (2007).
  CAS PubMed Google Scholar
• Nagar, B. et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859–871 (2003).
  CAS PubMed Google Scholar
• Nagar, B. et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236–4243 (2002).
  CAS PubMed Google Scholar